STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Clinical Endocrinology Update Steering Committee.
USE OF PROFESSIONAL JUDGMENT
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
DRUGS AND DOSAGES
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following CEU Committee Members reported relevant financial relationships:
Christine Burt Solorzano, MD: Research Support: Sanofi, Novo Nordisk, NIH NICHD Trial Net; Grantee: NIH NICHD, Waterloo Foundation.
Anders L. Carlson, MD: Research Investigator: Amgen, Insulet, Medtronic, Abbott, Dexcom, Sanofi, Novo Nordisk, Eli Lilly, UnitedHealth; Consulting/Advisory Board: Medtronic, Mannkind, Insulet, NovoNordisk.
Julia J. Chang, MD: Advisory Board: Crinetics, Camurus; Editorial Board: Endocrine Practice, AACE Diabetes and Endocrinology; Research Support: Recordati.
Ruchi Gaba, MD: Clinical Trial: Immunovant; Board Member: Texas Endocrinology Association.
Rodolfo Javier Galindo, MD: Grantee: Novo Nordisk, Boehringer, Roche, and Twiist/DEKA, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Consultant: Amgen, Bayer, Boehringer, Dexcom, Gan&Lee, Eli Lilly, Novo Nordisk, Medtronic; Boar of Directors: AACE.
Sagarika Gokul, MD: Volunteer Reviewer: Endocrine Practice Journal, ATA, AACE, Endocrine Society, Cureus Journal, BMJ; Sub-investigator: ONWARDS 11.
Amir Hekmat Hamrahian, MD: Consultant: GLG group, Reach Market Research, Checkpoint Capital, TD Securities, Leerink Partners, Elite Medical Experts, IQVIA, Corcept, Cristcot, Guidepoint Global, Neurocrine; Advisory Board: Recordati Rare Diseases, Corcept, Crinetics; Research Support: Corcept, Crinetics, Recordati, AstraZeneca, Spruce Biosciences.
Elizabeth Harris, MD: Advisory Board: Crinetics, Camurus, Novo Nordisk.
Vishnu Priya Pulipati, MD, FACE, DipABCL: Deputy Editor: American Association of Clinical Endocrinology - AACE Endocrine AI.
Jad G. Sfeir, MD: Advisory Committee: ASBMR - Professional Practice Committee.
Marcel Bartholomeus Twickler, MD, PhD: Working Group: "Health and Nutrition" in the "Hoge gezondheidsraad/Conseil Superieur de la Sante"; Investigator: PATRO Study; Editor: European Journal Clinical Investigation.
The following CEU steering committee members reported no financial relationships:
Beth Tupta, NP-C.
Disclosure information for presenters is included in their individual recorded presentations.
The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.
The relevant financial relationships listed for these individuals has been mitigated and there are no other relevant financial relationships with ineligible companies for those with the ability to control the content for this activity.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This program is supported by unrestricted educational grants from Arrowhead Pharmaceuticals, Inc., Corcept Therapeutics, Insulet, and Minimed.